Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Bacopa Monnieri | Modafinil | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands) | 100-200 mg once daily (for educational context only — prescription medication in most jurisdictions) |
| Timing | With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects. | Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours. |
| Cycle Duration | Ongoing; benefits accumulate over months. No strict cycling required. | Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use). |
| Evidence Level | strong_human | strong_human |
Active triterpenoid saponins (bacosides A and B) provide multifaceted neuroprotection: inhibition of acetylcholinesterase (AChE) and activation of choline acetyltransferase (ChAT) to enhance cholinergic neurotransmission; upregulation of tryptophan hydroxylase and serotonin transporter expression to modulate serotonergic tone; antioxidant neuroprotection via induction of superoxide dismutase and glutathione peroxidase; and reduction of beta-amyloid aggregation. Additionally enhances GABA signaling through GABA-A receptor subunit upregulation and glutamate decarboxylase activation.
300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands)
With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects.
Ongoing; benefits accumulate over months. No strict cycling required.
Atypical eugeroic (wakefulness-promoting agent) that primarily inhibits the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex and nucleus accumbens. This primary action cascades through multiple systems: indirect activation of orexinergic neurons in the lateral hypothalamus via potentiation of glutamatergic transmission; downstream stimulation of histaminergic neurons in the tuberomammillary nucleus (via orexin-mediated disinhibition of GABAergic inputs); and enhancement of norepinephrine release in the locus coeruleus. The net effect is broad-spectrum arousal without the peripheral sympathomimetic effects of classical stimulants.
100-200 mg once daily (for educational context only — prescription medication in most jurisdictions)
Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours.
Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use).
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →